Myeloproliferative Neoplasms | Topics

 
Patients With MPNs May Require More Cardiovascular Risk Management
June 14, 2021

Retrospective data presented at 2021 EHA revealed potential treatment gaps in the management of patients with myeloproliferative neoplasms.

FDA Grants Priority Review to Pacritinib for Treating Myelofibrosis With Severe Thrombocytopenia
June 02, 2021

The priority review designation for pacritinib is based off results from 3 trials investigating pacritinib 200 mg twice daily for patients with myelofibrosis and severe thrombocytopenia.

Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative Neoplasms
April 21, 2021

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.